Revenue and Profit Performance - Revenue for Q3 2024 was RMB 159.29 million, a decrease of 13.28% year-over-year[2] - Net profit attributable to shareholders for Q3 2024 was RMB 28.37 million, down 59.20% year-over-year[2] - Total revenue for the first three quarters of 2024 was 464.95 million USD, a decrease of 2.33% year-over-year[12] - Regular business revenue for the first three quarters of 2024 was 400.14 million USD, an increase of 12.32% year-over-year[12] - Non-regular business revenue for the first three quarters of 2024 was 44.78 million USD, a decrease of 59.76% year-over-year[12] - Net profit for the first three quarters of 2024 was 99.32 million USD, a decrease of 51.60% year-over-year[12] - Revenue for Q3 2024 was 159.29 million USD, a decrease of 13.28% year-over-year[12] - Regular business revenue for Q3 2024 was 135.69 million USD, an increase of 9.63% year-over-year[12] - Non-regular business revenue for Q3 2024 was 17.26 million USD, a decrease of 67.45% year-over-year[12] - Net profit for Q3 2024 was 28.37 million USD, a decrease of 59.20% year-over-year[12] - The decrease in net profit was primarily due to the decline in non-regular business revenue, fluctuations in cash management income, and the initial business expansion phase of the Suzhou subsidiary and Bioengineering Center (C4B), which have not yet generated sufficient revenue to cover operating costs[12] - Total operating revenue for the current period is RMB 464,949,715.92, a decrease of 2.34% compared to the previous period's RMB 476,061,706.26[18] - Net profit for the current period is RMB 99,315,298.46, a decrease of 51.6% compared to the previous period's RMB 205,197,148.65[19] - Basic earnings per share for the current period is RMB 0.7787, a decrease of 50.97% compared to the previous period's RMB 1.5882[20] - Total comprehensive income for the current period is RMB 96,767,089.35, a decrease of 50.64% compared to the previous period's RMB 196,081,756.32[20] Operating Costs and Expenses - Operating costs increased by 33.37% to RMB 118.95 million, driven by increased investment in CRO services and reagent business[6] - Total operating costs for the current period are RMB 412,226,046.80, a significant increase of 32.43% compared to the previous period's RMB 311,276,926.31[18] - R&D expenses for the current period are RMB 66,432,065.32, an increase of 8.84% compared to the previous period's RMB 61,037,480.06[18] - Cash paid to and for employees is RMB 231,710,616.18, an increase of 18.03% compared to the previous period's RMB 196,320,054.72[21] Cash Flow and Financial Position - Operating cash flow for the first nine months of 2024 was RMB 74.62 million, a decrease of 57.75% year-over-year[7] - The company's cash and cash equivalents decreased by 32.46% to RMB 888.82 million, primarily due to share repurchases[5] - The company's share repurchase program resulted in a net cash outflow of RMB 725.20 million from financing activities[7] - The company's monetary funds decreased from RMB 1,316.04 million at the beginning of the period to RMB 888.82 million at the end of the period[15] - Cash received from sales of goods and services is RMB 449,758,550.34, a decrease of 4.01% compared to the previous period's RMB 468,556,212.68[21] - Operating cash flow decreased to 74.62 million from 176.61 million, a significant drop[22] - Investment cash inflow increased to 9.04 billion from 7.72 billion, driven by higher returns on investments[22] - Investment cash outflow rose to 8.86 billion from 7.46 billion, primarily due to increased investment payments[22] - Net cash flow from financing activities was negative 725.20 million, compared to negative 274.87 million in the previous period[22] - Cash and cash equivalents at the end of the period decreased to 714.20 million from 1.19 billion at the beginning[22] Assets and Liabilities - Total assets as of the end of Q3 2024 were RMB 6.03 billion, a decrease of 8.64% compared to the end of the previous year[2] - Intangible assets increased by 5828.18% to RMB 47.39 million, mainly due to the acquisition of non-patented technology[5] - The company's total assets decreased from RMB 6,600.68 million at the beginning of the period to RMB 6,030.34 million at the end of the period[16] - The company's total liabilities increased from RMB 233.70 million at the beginning of the period to RMB 273.67 million at the end of the period[17] - The company's total equity decreased from RMB 6,366.98 million at the beginning of the period to RMB 5,756.67 million at the end of the period[17] - The company's inventory increased from RMB 52.53 million at the beginning of the period to RMB 64.24 million at the end of the period[15] - The company's accounts receivable increased from RMB 126.25 million at the beginning of the period to RMB 163.87 million at the end of the period[15] - The company's total current assets decreased from RMB 5,069.04 million at the beginning of the period to RMB 4,177.98 million at the end of the period[15] - The company's total non-current assets increased from RMB 1,531.64 million at the beginning of the period to RMB 1,852.36 million at the end of the period[16] Share Repurchase and Equity - The company completed the first phase of share repurchase, repurchasing 3,029,368 shares, accounting for 2.34% of the total shares before cancellation, with a total transaction amount of RMB 199.85 million[13][14] - The second phase of share repurchase has repurchased 4,533,890 shares, accounting for 3.59% of the total shares, with a total transaction amount of RMB 253.30 million[14] - The weighted average return on equity (ROE) for Q3 2024 was 0.50%, a decrease of 0.60 percentage points year-over-year[2] Government Subsidies and Other Income - Government subsidies received increased by 107.87% to RMB 7.82 million[6] - Other income for the current period is RMB 7,820,288.21, an increase of 107.91% compared to the previous period's RMB 3,762,051.75[19] - Interest income for the current period is RMB 16,460,451.20, a decrease of 56.41% compared to the previous period's RMB 37,759,118.82[19]
义翘神州(301047) - 2024 Q3 - 季度财报